Over 187,000 children under ten in central Gaza received the novel oral polio vaccine type 2 (nOPV2) during the first phase of a two-round polio vaccination campaign held from September 1–3, 2024. This phase surpassed the initial target of 157,000…
The World Health Organization (WHO) has officially designated the EngAGE Centre for Research in Ageing at Trinity College Dublin as its new Collaborating Centre for Longitudinal Studies on Ageing and the Life Course. This new Collaborating Centre will play a…
An exploratory analysis of the TROPION-Lung01 Phase III trial revealed that TROP2, as measured by AstraZeneca’s advanced computational pathology platform—quantitative continuous scoring (QCS)—was a predictor of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated…
AstraZeneca has finalized the studies supporting the regulatory filings for Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) to transition to a new, next-generation propellant. This propellant has a 99.9% lower Global Warming Potential compared to those used in current inhaled medications.…
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to present new 48-week data on its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place…
Interim results from the ongoing IDeate-Lung01 phase 2 trial show that ifinatamab deruxtecan (I-DXd) continues to deliver promising objective response rates in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). These findings, part of a press conference today, will…
Eli Lilly and Company (NYSE: LLY) and EVA Pharma have announced a new partnership aimed at increasing access to baricitinib for an estimated 20,000 individuals across 49 low- and middle-income countries in Africa by 2030. Developed by Incyte and licensed…
Daiichi Sankyo Europe (Daiichi Sankyo) has reaffirmed its commitment to addressing unmet needs and barriers in cardiovascular (CV) care by highlighting disparities in treatment and outcomes among different patient groups. This announcement follows the presentation of new data from sub-analyses…
Fresenius Kabi, a division of Fresenius, and the Association for the Advancement of Blood & Biotherapies (AABB) are excited to announce the commencement of the 19th annual Blood Collectors Week, taking place from September 1 through September 7, 2024. This…
Daiichi Sankyo Europe (Daiichi Sankyo) has reinforced its commitment to addressing unmet needs and disparities in cardiovascular care by emphasizing the differences in treatment and outcomes among diverse patient groups. This announcement follows the presentation of data from the SANTORINI…
Anthos Therapeutics, Inc., a cutting-edge clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular and metabolic diseases, announced significant findings from the AZALEA-TIMI 71 study at the European Society for Cardiology (ESC) Congress. The study revealed that approximately 1%…
ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady™, is thrilled to announce that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine’s Laboratory for Cell and Gene Medicine (LCGM), has been honored with…
